Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Total Current Liabilities (2020 - 2025)

Janux Therapeutics (JANX) has disclosed Total Current Liabilities for 6 consecutive years, with $25.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Current Liabilities rose 43.18% to $25.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $25.0 million, a 43.18% increase, with the full-year FY2025 number at $25.0 million, up 43.18% from a year prior.
  • Total Current Liabilities was $25.0 million for Q4 2025 at Janux Therapeutics, down from $27.8 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $27.8 million in Q3 2025 to a low of $9.2 million in Q2 2021.
  • A 5-year average of $15.9 million and a median of $16.1 million in 2023 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: soared 302.29% in 2021, then crashed 35.52% in 2024.
  • Janux Therapeutics' Total Current Liabilities stood at $12.8 million in 2021, then rose by 28.99% to $16.5 million in 2022, then decreased by 21.05% to $13.0 million in 2023, then skyrocketed by 33.96% to $17.5 million in 2024, then skyrocketed by 43.18% to $25.0 million in 2025.
  • Per Business Quant, the three most recent readings for JANX's Total Current Liabilities are $25.0 million (Q4 2025), $27.8 million (Q3 2025), and $21.4 million (Q2 2025).